Entities / Company
Scynexis.
company in Durham, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 13
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
FDA granted Orphan Drug Designation for SCY-770, a drug developed by Scynexis.Some support1 report
-
Renaissance Technologies and Geode Capital Management increased their stakes in Scynexis stock on June 27, 2026.Some support1 report
-
Christine Coyne was appointed CCO at Iterum Therapeutics, which is launching ORLYNVAH™ in the US.Some support2 reports
-
FDA lifted clinical hold on MARIO study and transferred the BREXAFEMME NDA to GSK.Some support1 report
-
Scynexis licensed its drug candidate ibrexafungerp to GSK.Some support2 reports
-
The TIMM-12 Congress is scheduled to take place in Bilbao, Spain.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Scynexis this week
News at the entities that move Scynexis most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Scynexis
-
GSK OperationalClement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.Moves Scynexis
-
Geode Capital Management StructuralGeode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Moves Scynexis
-
Renaissance Technologies TransactionalRenaissance Technologies holds a significant stake in Lite Strategy, Inc., whose stock trades on the Nasdaq exchange.Moves Scynexis
Connections
The 4 strongest of 13, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates Scynexis's clinical studies, product development, and market access through holds, designations, and approvals.
-
GSK Operational
GSK and Scynexis maintain an active, complex relationship involving drug licensing, milestone payments, and ongoing disputes.
-
Geode Capital Management Structural
Geode Capital Management established or increased its investment holdings in Scynexis.
-
Renaissance Technologies Transactional
Renaissance Technologies increased its financial stake in Scynexis stock.
History
Events by the month they beganAugust 2026
1 eventJune 2026
6 events- FDA granted Orphan Drug Designation for SCY-770, a drug developed by Scynexis.
- Renaissance Technologies and Geode Capital Management increased their stakes in Scynexis stock on June 27, 2026.
- Christine Coyne was appointed CCO at Iterum Therapeutics, which is launching ORLYNVAH™ in the US.
- FDA lifted clinical hold on MARIO study and transferred the BREXAFEMME NDA to GSK.
- Scynexis licensed its drug candidate ibrexafungerp to GSK.
- The TIMM-12 Congress is scheduled to take place in Bilbao, Spain.